Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Acasti Pharma (ACST)

Acasti Pharma (ACST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Acasti Pharma 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 CAN

www.acastipharma.com P: 609-649-9272 F: 450-686-2505

Description:

Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.

Key Statistics

Overview:

Market Capitalization, $K 28,856
Enterprise Value, $K 976
Shares Outstanding, K 9,399
Annual Sales, $ 0 K
Annual Net Income, $ -42,430 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,390 K
EBIT, $ -13,740 K
EBITDA, $ -13,620 K
60-Month Beta 1.49
% of Insider Shareholders 13.51%
% of Institutional Shareholders 6.08%
Float, K 8,130
% Float 86.49%
Short Volume Ratio 0.05

Growth:

1-Year Return 1.66%
3-Year Return -87.16%
5-Year Return -93.36%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 94.24%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.21 on 02/12/24
Latest Earnings Date 02/13/24
Earnings Per Share ttm -1.04
EPS Growth vs. Prev Qtr -10.53%
EPS Growth vs. Prev Year 61.10%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 07/10/23

ACST Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -13.18%
Return-on-Assets % -11.32%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.49
Book Value/Share 6.88
Interest Coverage -0.23
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar